Cellecta Blog & News
We have started the Cellecta blog as a simple, unobtrusive conduit that enables us to talk directly to our customers, collaborators, and other interested researchers about new and interesting developments related to Cellecta’s technology and business. Check back here often for the latest news and events.
Cellecta Inc., a custom and contract functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches for drug target and biomarker discovery. Our high throughput functional genetic screening portfolio includes shRNA and CRISPR screening services, custom and off-the-shelf pooled libraries, and knockout/knockdown cell lines that facilitate genome-wide functional screening and the identification and validation of genes involved in critical biological and pathological responses.
With our new DriverMap™ Gene Expression and Molecular Profiling Service, Cellecta now offers a quantitative, multiplexed approach that allows simultaneous profiling of thousands of genes in one reaction, thereby providing the transcriptome profile of the tumor microenvironment.
Researchers at the German Cancer Research Center (DKFZ) used Cellecta's shRNA DECIPHER libraries to identify genes that sensitize pancreatic cells to gemcitabine. Pancreatic cancer has only a 6% 5-year survival rate. Gemcitabine is the standard treatment in...read more
At Cellecta, we have relied primarily on lentiviral vectors to develop our RNAi genetic screening technology. The broad tropism of lentivirus-based plasmids packaged into VSV-g pseudotyped viral particles provides a very convenient vector system to introduce and...read more
2013 seems to have started at a full sprint. It feels as though the annual meeting of the American Society of Cell Biology in San Francisco just finished. We exhibited and presented a tutorial there entitled, Find Functionally Important Driver Genes with RNAi Genetic...read more
Second Phase SBIR Contract from the National Cancer Institute (NCI) to Identify Lethal Gene Combinations in Cancer Cell Models
It's been a while since the last post to this blog. It is not that nothing has been going on, in fact, quite the opposite. It has been quite busy the past several months and, unfortunately, blog postings have suffered. However, I thought I would get things started...read more
Our group recently ran across an article describing an independent RNAi screen with a non-Cellecta pooled shRNA expression library that piqued our interest. In the October 2011 online Genome Biology Journal, Sims, et al. comprehensively described how to run a rigorous...read more
A couple of months ago at the CHI Discovery on Target Conference, Hakim Djaballah, Director of the HTS Core Facility at the Memorial Sloan Kettering Cancer Center, gave a unique and insightful presentation highlighting the challenges RNAi screening to identify lethal...read more
We recently received a phase II of our SBIR grant Exploiting Synthetic Lethality of Hematopoietic Lineage Cells to Develop Novel Targets from the NIH. Rather than trying to identify potential drug targets in oncogenic hematopoietic cells, much of the effort for this...read more
Therapeutic approaches using multiple drug combinations have become a standard treatment model for many types of cancer. Due to the tremendous genetic complexity and adaptive nature of most human malignancies, the use of multiple drugs acting on different targets...read more
The last blog entry discussed how hairpin structural features affect representation and effectiveness of shRNA sequences in pooled libraries. However, it is clear that the nucleotide sequence is possibly the major factor that determines the efficiency at which...read more
We have done a significant amount of evaluation to identify features of the optimal shRNA structure necessary to ensure our complex libraries maintain and express representative and effective shRNA. Independent from particular targeting sequences, structural...read more
Inducible expression is often desirable for functional genetic testing to establish clear cause and effect for a specific phenotype. A particular phenotype can be demonstrably linked to expression of a specific cDNA by showing it disappears when transcription...read more
Researchers are often interested in using a pooled shRNA library for genome-wide RNAi screening to cast a very “wide and unbiased net to identify any and all genes functionally involved in some pathway”. Although it is not difficult to make an shRNA library targeting...read more
Take the opportunity at SBS 2011 to learn about Cellecta's cancer drug target discovery services. Come visit us at booth #522, and be sure not to miss our oral presentation and tutorial on Wednesday, March 30: 11:00-11:30am HT RNAi Screening of Anti-Cancer Targets...read more
Cellecta attended the AACR-NCI Systems Biology : Confronting the Complexity of Cancer Conference in San Diego last week and presented two posters: Identification and Analysis of Essential Genes in Leukemic Cell Lines Using RNAi Screening and HT Screening for Bioactive Peptides that Increase Radiation Tolerance Using a Pooled Lentiviral Peptide Scanning Library. Here we present a summary of the conference and our experiences.read more
The addition of the 3rd DECIPHER Human shRNA Expression Library Module to the DECIPHER pooled shRNA library collection adds approximately 5,000 new cell surface, extracellular, and DNA binding target genes to the 10,000 well-annotated signal transduction and disease-associated genes targeted by the other two Human shRNA expression library modules that have been available since last October.read more
Since we provide both constitutive and tetracycline-inducible versions of both U6 and H1 shRNA promoters, we often get questions regarding which to choose or which is “better.” In fact, our data with both promoters indicates they function equally well, so it is difficult to provide a clear-cut answer.read more